$Corvus制药(CRVS)$ Roth Capital analyst Tony Butler keeps a Buy rating on Corvus Pharmaceuticals (CRVS) with a $6 price target after the company published an update on its Covid-19 trial for anti-CD73 antibody mupadolimab.
看看能不能回到6？？？
| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$Corvus制药(CRVS)$ Roth Capital analyst Tony Butler keeps a Buy rating on Corvus Pharmaceuticals (CRVS) with a $6 price target after the company published an update on its Covid-19 trial for anti-CD73 antibody mupadolimab.
看看能不能回到6？？？